# Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

> **NCT02163499** · PHASE3 · COMPLETED · sponsor: **ZS Pharma, Inc.** · enrollment: 751 (actual)

## Conditions studied

- Hyperkalemia

## Interventions

- **DRUG:** Sodium Zirconium Cyclosilicate

## Key facts

- **NCT ID:** NCT02163499
- **Lead sponsor:** ZS Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-30
- **Primary completion:** 2016-11-30
- **Final completion:** 2016-11-30
- **Target enrollment:** 751 (ACTUAL)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02163499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02163499, "Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02163499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*